Latest Breaking News On - Marketing authorizations - Page 1 : comparemela.com

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C difficile Infection

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobertj delucciaTrial oversight committeeDrug administrationData monitoring committeeAcurx pharmaceuticals incCompany scientific advisory boardAcurx pharmaceuticalsAdvice meetingModified intent to treatClinical cureExecutive chairmanNew drug applicationMarketing authorizationsIbezapolstat phaseScientific advisory board

AstraZeneca says it s withdrawing COVID vaccine amid low demand - National

AstraZeneca says it s withdrawing COVID vaccine amid low demand - National
globalnews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalnews.ca Daily Mail and Mail on Sunday newspapers.

Astrazeneca vaxzevriaDavid williamsEuropean unionCanada national advisory committee on immunizationGlobal newsMarketing authorizationsNational advisory committee

Small-cap Shares Fall Sharply - Monday Closing Report

On Monday, 925 stocks advanced, 3039 declined and 118 remained unchanged, with an advance decline ratio of 0.30 on the Bombay Stock Exchange (BSE), indicating negative closing of stocks in broader markets.

United statesKashipur uttarakhandGanesh benzoplastZydus lifesciencesBombay stock exchangeAdani green energyGmk centerSun pharmaceutical industries incGreen hydrogen derivativesAuthority of indiaLotus eye hospital and instituteRenewable energyWaterways authority of indiaBattery energy storage systemsMacrotech developersEnterpreneurship foundation mk group

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C difficile Infection

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavidp luciRobertj delucciaTrial oversight committeeAcurx pharmaceuticals incData monitoring committeeCompany scientific advisory boardEuropean medicines agency onDrug administrationAcurx pharmaceuticalsNew drug applicationMeeting requestMeeting packageBriefing documentEuropean medicines agencyScientific advice

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2.

United statesDavidp luciPrnewswire acurx pharmaceuticals incCompany scientific advisory boardAcurx pharmaceuticalsEuropean medicines agencyExchange commission on formSociety or healthcare epidemiology of americaDrug administrationData monitoring committeeInfectious diseases society of americaAcurx pharmaceuticals incTrial oversight committeeCompany phBriefing documentMedium sized enterprise